44483637 2024-01-01 2024-12-31 44483637 2024-01-01 2024-12-31 auditor_1 44483637 2024-01-01 2024-12-31 memberOfBoardIdentifier_1 44483637 2024-01-01 2024-12-31 memberOfBoardIdentifier_1 44483637 2024-01-01 2024-12-31 memberOfBoardIdentifier_2 44483637 2024-01-01 2024-12-31 memberOfBoardIdentifier_3 44483637 2023-12-01 2023-12-31 44483637 2024-12-31 44483637 2023-12-31 44483637 2023-12-31 fsa:ContributedCapitalMember 44483637 2023-12-31 fsa:ReserveForUnpaidContributedCapitalMember 44483637 2023-12-31 fsa:RetainedEarningsMember 44483637 2023-12-31 fsa:ProposedDividendRecognisedInEquityMember 44483637 2024-01-01 2024-12-31 fsa:ContributedCapitalMember 44483637 2024-01-01 2024-12-31 fsa:ReserveForUnpaidContributedCapitalMember 44483637 2024-01-01 2024-12-31 fsa:RetainedEarningsMember 44483637 2024-01-01 2024-12-31 fsa:ProposedDividendRecognisedInEquityMember 44483637 2024-12-31 fsa:ContributedCapitalMember 44483637 2024-12-31 fsa:ReserveForUnpaidContributedCapitalMember 44483637 2024-12-31 fsa:RetainedEarningsMember 44483637 2024-12-31 fsa:ProposedDividendRecognisedInEquityMember 44483637 2023-12-31 fsa:CompletedDevelopmentProjectsMember 44483637 2024-12-31 fsa:CompletedDevelopmentProjectsMember 44483637 2024-01-01 2024-12-31 fsa:CompletedDevelopmentProjectsMember 44483637 2023-12-31 fsa:OtherInvestmentsMember 44483637 2024-01-01 2024-12-31 fsa:OtherInvestmentsMember 44483637 2024-12-31 fsa:OtherInvestmentsMember iso4217:DKK pure Årsrapport 2024-01-01 2023-12-01 2024-12-31 2023-12-31 2025-06-25 44483637 2025-06-25 2023-12-08 Reporting class B KPMG 2100 København Ø Dampfærgevej 28 25578198 Auditor's reports (Other non-assurance reports) Copenhagen 2025-06-25 KPMG 25578198 true Matias Søndergaard The Board of Directors and the Executive Board have today discussed and approved the annual report for Coco Care ApS for the financial year 1 January - 31 December 2024. The annual report, which has not been audited, is presented in accordance with the Danish Financial Statements Act. In our opinion, the financial statements give a true and fair view of the Company's assets, liabilities and financial position at 31 December 2024 and of the results of the Company's operations for the financial year 1 January - 31 December 2024.Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review. We recommend that the annual report be approved at the annual general meeting. Management confirms that the Company fulfils the requirement to be exempt from audit. Matias Søndergaard Mikkel Lucas Overby Chairman Matias Søndergaard Karen Skjerbæk Jørgensen Auditor's report on compilation of financial statements To the Management of Coco Care ApS We have compiled the financial statements of Coco Care ApS for the financial year 1 January - 31 December 2024 based on the Company's bookkeeping records and other information provided by you.The financial statements comprise income statement, balance sheet, statement of changes in equity and notes, including accounting policies.We performed our work in accordance with ISRS 4410 Compilation Engagements.We have applied our professional expertise in accounting and financial reporting to assist you in the preparation and presentation of these financial statements in accordance with the Danish Financial Statements Act. We have complied with relevant provisions of the Danish Auditor Act, including the requirements for independence, and International Ethics Standards Board for Accountants’ International Code of Ethics for Professional Accountants (IESBA Code), which is based on fundamental principles of integrity, objectivity, professional competence and due care.These financial statements and the accuracy and completeness of the information used to compile them are your responsibility. Since a compilation engagement is not an assurance engagement, we are not required to verify the accuracy or completeness of the information you provided to us to compile these financial statements. Accordingly, we do not express an audit opinion or a review conclusion as to whether these financial statements are prepared in accordance with the Danish Financial Statements Act. Simon Vinberg Andersen mne35458 Coco Care ApS Sankt Gertruds Stræde 10 DK-1129 København K København Principal activities The company's purpose is development and delivery of products and services within Health-tech and related business areas as deemed appropriate by the board. Development in activities and financial position The Company's income statement for 2024 shows a profit of DKK 8,598,699 as against a loss of DKK 172,752 in 1 December - 31 December 2023. Equity in the Company's balance sheet at 31 December 2024 stood at DKK 4,126,342 as against DKK 4,596,644 at 31 December 2023. The profit for 2024 is significantly impacted by a fair value adjustment to Other securities and equity investments of DKK 11,449,000 related to the distribution of those assets. Events after the balance sheet date No events have occurred after the balance sheet date of material importance to the annual report for 2024. 8950942 -150508 517203 30189 412368 34364 8021371 -215061 2495 50 2151 5056 8021715 -220067 -576984 -47315 8598699 -172752 11569000 0 -2970301 -172752 3676962 0 0 0 36451 0 25531 0 0 0 0 0 1064133 255389 4803077 5176303 204045 178400 0 700000 3922297 3718244 4126342 4596644 0 576984 0 576984 96006 0 24729 2675 556000 0 676735 2675 676735 2675 4803077 5176303 178400 700000 3718244 0 25645 0 2474354 0 0 -700000 700000 0 0 0 -2970301 11569000 0 0 0 -11569000 204045 0 3922297 0 The annual report of Coco Care ApS for 2024 has been prepared in accordance with the provisions applying to reporting class B entities under the Danish Financial Statements Act with opt-in from higher reporting classes.The accounting policies used in the preparation of the financial statements are consistent with those of last year. Revenue Income from the sale of goods, comprising the sale of products and services, are recognised in revenue when delivery and transfer of risk to the buyer have taken place, and the income may be measured reliably and is expected to be received. The date of transfer of the most significant benefits and risks is determined using standard Incoterms ®2020. Revenue is measured at the fair value of the agreed consideration excluding VAT and taxes charged on behalf of third parties. All discounts granted are deducted from revenue. Revenue from the sale of services is recognised on a straight-line basis in the income statement as the services are provided. Cost of sales Cost of sales comprises costs incurred to generate revenue for the year. This item also comprises direct costs for goods for resale and changes to inventory of goods for resale. Other operating income Other operating income comprises items secondary to the activities of the Company, including fair value adjustment of other equity investments. Other external costs Other external costs comprise costs for administrative expenses, costs of premises, etc. Staff costs Staff costs comprise wages and salaries, including holiday allowance, pension and other social security costs. Financial income and expenses Financial income and expenses comprise interest income and expense. Tax on profit/loss for the year Tax for the year comprises current tax for the year and changes in deferred tax, including changes in tax rates. The tax expense relating to the profit/loss for the year is recognised in the income statement at the amount attributable to the profit/loss for the year and directly in equity at the amount attributable to entries directly in equity. Intangible assets Patents and licences are measured at cost less accumulated amortisation and impairment losses. Patents are amortised on a straight-line basis over the remaining life of the patent, and licences are amortised over the contract period, however, not exceeding # years. Development costs and costs for internally generated rights are recognised in the income statement in the acquisition year. Gains and losses on the disposal of intangible assets are determined as the difference between the selling price less selling costs and the carrying amount at the date of disposal. Gains and losses are recognised in the income statement as other operating income or other operating costs, respectively. Financial assets Other securities and equity investments included in investment comprise unlisted shares that Management considers investment securities. The equity investments are measured at cost. Impairment of fixed assets The carrying amount of intangible assets and property, plant and equipment as well as equity investments in group entities and participating interests (including associates) is subject to an annual test for indications of impairment other than the decrease in value reflected by depreciation or amortisation. Impairment tests are conducted of individual assets or groups of assets when there is an indication that they may be impaired. Write-down is made to the recoverable amount if this is lower than the carrying amount. The recoverable amount is the higher of an asset's net selling price and its value in use. The value in use is determined as the present value of the forecast net cash flows from the use of the asset or the group of assets, including forecast net cash flows from the disposal of the asset or the group of assets after the end of the useful life. Previously recognised write-downs are reversed when the basis for the write-down no longer exists. Receivables Receivables are measured at amortised cost. Write-down is made for bad debt losses where there is an objective indication that a receivable has been impaired. If there is an objective indication that an individual receivable has been impaired, write-down is made on an individual basis. Write-downs are calculated as the difference between the carrying amount of receivables and the present value of forecast cash flows, including the realisable value of any collateral received. The effective interest rate for the individual receivable or portfolio is used as discount rate. Prepayments Prepayments comprise prepayment of costs incurred relating to subsequent financial years. Cash at bank and in hand Cash at bank and in hand comprise cash and bank deposits. EquityDividends The expected dividend payment for the year is disclosed as a separate item under equity. Corporation tax and deferred tax Deferred tax is measured using the balance sheet liability method on all temporary differences between the carrying amount and the tax value of assets and liabilities measured on the planned use of the asset or settlement of the liability, respectively. However, deferred tax is not recognised on temporary differences relating to office buildings non-deductible for tax purposes and other items where temporary differences arise at the date of acquisition without affecting either profit/loss or taxable income. Deferred tax is measured in accordance with the tax rules and at the tax rates applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Changes in deferred tax as a result of changes in tax rates are recognised in the income statement or equity, respectively. Liabilities other than provisions Liabilities are measured at amortised cost. Deferred income Deferred income comprises payments received regarding income in subsequent years. 513113 30000 4090 189 1 1 -576984 -47315 4123694 4123694 -34364 -412368 -446732 3676962 120000 -120000 0 0 11449000 -11449000 0 0